

Supplementary Online Content

Basu S, Zhang T, Gilmore A, Datta E, Kim EY. Utilization and cost of an employer-sponsored comprehensive primary care delivery model. *JAMA Netw Open*. 2020;3(4):e203803. doi:10.1001/jamanetworkopen.2020.3803

eTable 1. Specialty Designations of Primary Care Providers

eTable 2. Allowed Amount Schedule (by Visit Code) for Common Current Procedural Terminology (CPT) Billing Codes

eTable 3. Unadjusted Descriptive Statistics Among Persons Primarily Using the On-Site Clinic Versus Primarily Using the Near-Site Clinics for Their Primary Care Evaluation and Management Visits

eTable 4. Percent Differences in Spending (\$US 2019)

eTable 5. Percent Differences in Utilization (Encounters per 1,000 Member Months)

eTable 6. Percent Differences in Spending per Encounter (\$US 2019/Encounter)

eTable 7. Sensitivity Analysis on Percent Differences in Spending (\$US 2019)

eTable 8. Sensitivity Analysis on Percent Differences in Utilization (Encounters per 1,000 Member Months)

eTable 9. Sensitivity Analysis on Percent Differences in Spending per Encounter (\$US 2019/encounter)

eTable 10. Descriptive Statistics for the Primary Treatment Group Versus the Alternative Control Group of Unsubsidized Members From Other Employers

eTable 11. Sensitivity Analysis of Alternative Control Group

eTable 12. Sensitivity Analysis on Percent Differences in Spending (\$US 2019)

eTable 13. Sensitivity Analysis on Percent Differences in Utilization (Encounters per 1,000 Member Months)

eTable 14. Sensitivity Analysis on Percent Differences in Spending per Encounter (\$US 2019/Encounter)

eFigure 1. Quantile-Quantile Plot of Log-Transformed Total Medical and Pharmaceutical Spending (\$US 2019) Compared to the Theoretically-Optimal Line For Ordinary Least Squares Regression

eFigure 2. Absolute Differences in Spending, Utilization, and Spending per Encounter

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Specialty designations of primary care providers.

General Practice
Pediatrics
Family Medicine
Adolescent Medicine
Adult Medicine
Geriatric Medicine
Internal Medicine

eTable 2. Allowed amount schedule (by visit code) for common Current Procedural Terminology (CPT) billing codes.

CPT	Fee (\$US 2019)	Description
10040	209.21	Acne surgery
10060	226.71	Drainage of skin abscess
10061	390.16	Drainage of skin abscess
10080	358.1	Drainage of pilonidal cyst
10081	528.99	Drainage of pilonidal cyst
10120	294.12	Remove foreign body
10160	249.4	Puncture drainage of lesion
11000	105.68	Debride infected skin
11055	109.96	Trim skin lesion
11056	130.58	Trim skin lesions 2 to 4
11102	191.7	Tangntl bx skin single les
11103	103.15	Tangntl bx skin ea sep/addl
11104	241.08	Punch bx skin single lesion
11105	117.98	Punch bx skin ea sep/addl
11106	291.51	Incal bx skn single les
11107	139.07	Incal bx skn ea sep/addl
11200	169.47	Removal of skin tags <w/15
11201	35.02	Remove skin tags add-on
11300	190.33	Shave skin lesion 0.5 cm/<
11301	231.68	Shave skin lesion 0.6-1.0 cm
11302	270.95	Shave skin lesion 1.1-2.0 cm
11303	297.7	Shave skin lesion >2.0 cm
11305	198.3	Shave skin lesion 0.5 cm/<
11306	235.06	Shave skin lesion 0.6-1.0 cm
11307	277.6	Shave skin lesion 1.1-2.0 cm
11310	220.65	Shave skin lesion 0.5 cm/<
11311	262	Shave skin lesion 0.6-1.0 cm
11312	306.28	Shave skin lesion 1.1-2.0 cm
11400	240.65	Exc tr-ext b9+marg 0.5 cm<
11401	290.76	Exc tr-ext b9+marg 0.6-1 cm
11402	322.45	Exc tr-ext b9+marg 1.1-2 cm
11403	370.18	Exc tr-ext b9+marg 2.1-3cm
11406	594.47	Exc tr-ext b9+marg >4.0 cm
11420	240.2	Exc h-f-nk-sp b9+marg 0.5/<
11421	302.5	Exc h-f-nk-sp b9+marg 0.6-1
11422	340	Exc h-f-nk-sp b9+marg 1.1-2
11440	266.54	Exc face-mm b9+marg 0.5 cm/<
11441	325.67	Exc face-mm b9+marg 0.6-1 cm
11442	362.22	Exc face-mm b9+marg 1.1-2 cm
11600	374.18	Exc tr-ext mal+marg 0.5 cm/<
11601	439.2	Exc tr-ext mal+marg 0.6-1 cm
11602	475.23	Exc tr-ext mal+marg 1.1-2 cm
11603	540.21	Exc tr-ext mal+marg 2.1-3 cm
11620	376.66	Exc h-f-nk-sp mal+marg 0.5/<
11621	440.97	Exc s/n/h/f/g mal+mrg 0.6-1
11622	490.34	Exc s/n/h/f/g mal+mrg 1.1-2
11640	388.54	Exc f/e/e/n/1 mal+mrg 0.5cm<
11641	456.36	Exc f/e/e/n/1 mal+mrg 0.6-1
11642	518.15	Exc f/e/e/n/1 mal+mrg 1.1-2
11730	209.56	Removal of nail plate
11732	62.4	Remove nail plate add-on
11740	100.25	Drain blood from under nail
11750	298.27	Removal of nail bed
11760	370.95	Repair of nail bed
11900	103.59	Inject skin lesions </w 7
11901	129.42	Inject skin lesions >7
11980	179.49	Implant hormone pellet(s)
11981	269.31	Insert drug implant device

11982	297.12	Remove drug implant device
11983	427.62	Remove/insert drug implant
12001	170.44	Rpr s/n/ax/gen/trnk 2.5cm/<
12002	206.09	Rpr s/n/ax/gen/trnk2.6-7.5cm
12011	207.65	Rpr f/e/e/n/l/m 2.5 cm/<
12021	315.19	Closure of split wound
15786	473.66	Abrasion lesion single
15787	87.32	Abrasion lesions add-on
16000	132.27	Initial treatment of burn(s)
17000	124.68	Destruct premalg lesion
17003	10.8	Destruct premalg les 2-14
17004	290.76	Destroy premal lesions 15/>
17110	214.9	Destruct b9 lesion 1-14
17111	252.92	Destruct lesion 15 or more
17250	158.63	Chem caut of granltj tissue
17260	181.44	Destruction of skin lesions
17261	278.28	Destruction of skin lesions
17262	337.41	Destruction of skin lesions
17263	367.66	Destruction of skin lesions
17270	285.48	Destruction of skin lesions
17271	314.19	Destruction of skin lesions
17272	357.84	Destruction of skin lesions
17280	268.01	Destruction of skin lesions
17281	341.13	Destruction of skin lesions
17282	390.87	Destruction of skin lesions
19000	212.49	Drainage of breast lesion
20526	144.66	Ther injection carp tunnel
20550	99.04	Inj tendon sheath/ligament
20551	100.76	Inj tendon origin/insertion
20552	104.62	Inj trigger point 1/2 muscl
20553	120.72	Inject trigger points 3/>
20600	90.78	Drain/inj joint/bursa w/o us
20604	139.69	Drain/inj joint/bursa w/us
20605	94.9	Drain/inj joint/bursa w/o us
20606	153.91	Drain/inj joint/bursa w/us
20610	112.1	Drain/inj joint/bursa w/o us
20611	172.91	Drain/inj joint/bursa w/us
20612	113.69	Aspirate/inj ganglion cyst
24640	191.58	Treat elbow dislocation
28190	502.64	Removal of foot foreign body
29125	124.42	Apply forearm splint
29130	77.38	Application of finger splint
29515	136.26	Application lower leg splint
30300	362.15	Remove nasal foreign body
40490	241.22	Biopsy of lip
40808	370.04	Biopsy of mouth lesion
40819	613.1	Excise lip or cheek fold
41010	407.02	Incision of tongue fold
46083	354.94	Incise external hemorrhoid
46320	365.22	Removal of hemorrhoid clot
46600	186.87	Diagnostic anoscopy spx
46601	264.99	Diagnostic anoscopy
46607	373.06	Diagnostic anoscopy & biopsy
46910	502.48	Destruction anal lesion(s)
46916	464.03	Cryosurgery anal lesion(s)
46922	544.2	Excision of anal lesion(s)
54056	271.73	Cryosurgery penis lesion(s)
54065	420.48	Destruction penis lesion(s)
54100	379.59	Biopsy of penis
56405	214.26	I & d of vulva/perineum
56420	258.42	Drainage of gland abscess
56501	273.83	Destroy vulva lesions sim
56515	442.23	Destroy vulva lesion/s compl
56605	160.37	Biopsy of vulva/perineum
56606	70.99	Biopsy of vulva/perineum
56820	214.86	Exam of vulva w/scope

56821	285.71	Exam/biopsy of vulva w/scope
57061	235.59	Destroy vag lesions simple
57065	386.28	Destroy vag lesions complex
57100	173.08	Biopsy of vagina
57170	121.42	Fitting of diaphragm/cap
57420	225.59	Exam of vagina w/scope
57421	302.17	Exam/biopsy of vag w/scope
57452	213.59	Exam of cervix w/scope
57454	290.78	Bx/curett of cervix w/scope
57455	276.24	Biopsy of cervix w/scope
57456	260.12	Endocerv curettage w/scope
57500	256.93	Biopsy of cervix
57505	213.24	Endocervical curettage
57510	256.16	Cauterization of cervix
57511	293.54	Cryocautery of cervix
57513	304.03	Laser surgery of cervix
58100	174.17	Biopsy of uterus lining
58110	93.6	Bx done w/colposcopy add-on
58300	150.4	Insert intrauterine device
58301	177.97	Remove intrauterine device
59425	846.6	Antepartum care only
59426	1514.36	Antepartum care only
59430	361.3	Care after delivery
62322	294.36	Njx interlaminar lmbtr/sac
64400	260.42	Njx aa&/strd trigeminal nrv
64450	148.09	Njx aa&/strd other pn/branch
64455	89.23	N block inj plantar digit
64505	221.37	N block spenopalatine gangl
67810	342.19	Biopsy eyelid & lid margin
67850	417.83	Treat eyelid lesion
69100	189.21	Biopsy of external ear
69200	156.32	Clear outer ear canal
69209	28.22	Remove impacted ear wax uni
69210	88.62	Remove impacted ear wax uni
76801	236.7	Ob us < 14 wks single fetus
76801	236.7	Ob us < 14 wks single fetus
76801	236.7	Ob us < 14 wks single fetus
76802	120.67	Ob us < 14 wks addl fetus
76802	120.67	Ob us < 14 wks addl fetus
76802	120.67	Ob us < 14 wks addl fetus
76815	163.01	Ob us limited fetus(s)
76815	163.01	Ob us limited fetus(s)
76815	163.01	Ob us limited fetus(s)
76817	186.87	Transvaginal us obstetric
76817	186.87	Transvaginal us obstetric
76817	186.87	Transvaginal us obstetric
76830	238.24	Transvaginal us non-ob
76830	238.24	Transvaginal us non-ob
76830	238.24	Transvaginal us non-ob
76881	172.73	Us compl joint r-t w/img
76881	172.73	Us compl joint r-t w/img
76881	172.73	Us compl joint r-t w/img
76882	110.41	Us lmtd jt/nonvasc xtr strux
76882	110.41	Us lmtd jt/nonvasc xtr strux
76882	110.41	Us lmtd jt/nonvasc xtr strux
76942	108.27	Echo guide for biopsy
76942	108.27	Echo guide for biopsy
76942	108.27	Echo guide for biopsy
86580	16.82	Tb intradermal test
90460	31.86	Im admin 1st/only component
90461	24.18	Im admin each addl component
90471	31.86	Immunization admin
90472	24.18	Immunization admin each add
90473	31.86	Immune admin oral/nasal
90474	24.18	Immune admin oral/nasal addl
90632	97.91	Hepa vaccine adult im

90656	33.23	Iiv3 vacc no prsv 0.5 ml im
90662	89.68	Iiv no prsv increased ag im
90670	344.64	Pcv13 vaccine im
90674	40.41	Cciiiv4 vac no prsv 0.5 ml im
90675	487.22	Rabies vaccine im
90685	36.66	Iiv4 vacc no prsv 0.25 ml im
90686	31.98	Iiv4 vacc no prsv 0.5 ml im
90688	29.97	Iiv4 vaccine spl't 0.5 ml im
90691	117.43	Typhoid vaccine im
90714	38.86	Td vacc no presv 7 yrs+ im
90715	54.33	Tdap vaccine 7 yrs/> im
90732	181.04	Ppsv23 vacc 2 yrs+ subq/im
90740	218.84	Hepb vacc 3 dose immunosup im
90744	43.92	Hepb vacc 3 dose ped/adol im
90746	109.42	Hepb vaccine 3 dose adult im
90756	38.3	Cciiiv4 vacc abx free im
90791	250.23	Psych diagnostic evaluation
90792	281	Psych diag eval w/med srvc
90832	122.06	Psytx w pt 30 minutes
90833	126.46	Psytx w pt w e/m 30 min
90834	162.41	Psytx w pt 45 minutes
90836	160.06	Psytx w pt w e/m 45 min
90837	243.82	Psytx w pt 60 minutes
90838	211.44	Psytx w pt w e/m 60 min
90839	254.19	Psytx crisis initial 60 min
90840	122.06	Psytx crisis ea add'l 30 min
93000	32.28	Electrocardiogram complete
93005	16.82	Electrocardiogram tracing
94010	69.34	Breathing capacity test
94010	69.34	Breathing capacity test
94010	69.34	Breathing capacity test
94150	50.18	Vital capacity test
94150	50.18	Vital capacity test
94150	50.18	Vital capacity test
94640	36.06	Airway inhalation treatment
94664	33.92	Evaluate pt use of inhaler
94760	4.7	Measure blood oxygen level
95115	18.24	Immunotherapy one injection
95117	21.09	Immunotherapy injections
96150	41.78	Health and behavior assessment
96151	40.93	Health and behavior assessment
96160	6.42	Pt-focused hlth risk assmt
96372	31.86	Ther/proph/diag inj sc/im
97014	28.22	Electric stimulation therapy
97032	27.66	Electrical stimulation
97035	25.84	Ultrasound therapy
97110	57.86	Therapeutic exercises
97112	66.01	Neuromuscular reeducation
97116	57.14	Gait training therapy
97140	52.61	Manual therapy 1/> regions
97161	160.07	Pt eval low complex 20 min
97162	160.07	Pt eval mod complex 30 min
97163	160.07	Pt eval high complex 45 min
97164	109.35	Pt re-eval est plan care
97530	76.47	Therapeutic activities
97597	174.98	Rmvl devital tis 20 cm/<
97760	91.67	Orthotic mgmt&traing 1st enc
97810	67.48	Acupunct w/o stimul 15 min
97811	50.75	Acupunct w/o stimul add'l 15m
97813	74.21	Acupunct w/stimul 15 min
97814	59.62	Acupunct w/stimul add'l 15m
98925	58.91	Osteopath manj 1-2 regions
98926	84.43	Osteopath manj 3-4 regions
98927	110.66	Osteopath manj 5-6 regions
98928	134.04	Osteopath manj 7-8 regions
98929	160.28	Osteopath manj 9-10 regions

98940	52.79	Chiropract manj 1-2 regions
98941	76.46	Chiropract manj 3-4 regions
98942	98.42	Chiropractic manj 5 regions
98943	50.36	Chiropract manj xtrspnl 1/>
98960	54.3	Self-mgmt educ & train 1 pt
98966	25.53	Hc pro phone call 5-10 min
98967	49.33	Hc pro phone call 11-20 min
98968	72.71	Hc pro phone call 21-30 min
99173	5.41	Visual acuity screen
99201	86.67	Office/outpatient visit new
99202	143.52	Office/outpatient visit new
99203	202.02	Office/outpatient visit new
99204	304.57	Office/outpatient visit new
99205	381.76	Office/outpatient visit new
99211	43.9	Office/outpatient visit est
99212	85.54	Office/outpatient visit est
99213	139.22	Office/outpatient visit est
99214	203.27	Office/outpatient visit est
99215	271.09	Office/outpatient visit est
99241	89.26	Office consultation
99242	166.64	Office consultation
99243	227.76	Office consultation
99244	338.54	Office consultation
99245	411.96	Office consultation
99354	238.41	Prolong e&m/psycctx serv o/p
99381	208.55	Init pm e/m new pat infant
99382	218.16	Init pm e/m new pat 1-4 yrs
99383	226.63	Prev visit new age 5-11
99384	255.02	Prev visit new age 12-17
99385	246.68	Prev visit new age 18-39
99386	285.32	Prev visit new age 40-64
99387	309.33	Init pm e/m new pat 65+ yrs
99391	187.78	Per pm reeval est pat infant
99392	200	Prev visit est age 1-4
99393	199.29	Prev visit est age 5-11
99394	218.08	Prev visit est age 12-17
99395	222.67	Prev visit est age 18-39
99396	236.87	Prev visit est age 40-64
99397	255.02	Per pm reeval est pat 65+ yr
99401	73.72	Preventive counseling indiv
99402	119.48	Preventive counseling indiv
99403	164.68	Preventive counseling indiv
99404	209.81	Preventive counseling indiv
99406	27.45	Behav chng smoking 3-10 min
99495	308.74	Trans care mgmt 14 day disch
99496	434.65	Trans care mgmt 7 day disch
99497	156.23	Advncd care plan 30 min
G0101	73.37	Ca screen;pelvic/breast exam
G0402	310.6	Initial preventive exam
G0438	321	Ppps, initial visit
G0439	218.95	Ppps, subseq visit
J0171	1.25	Adrenalin epinephrine inject
J0561	23.28	Penicillin g benzathine inj
J0585	10.32	Injection,onabotulinumtoxina
J0696	1.09	Ceftriaxone sodium injection
J0702	11.59	Betamethasone acet&sod phosp
J1030	11.09	Methylprednisolone 40 mg inj
J1040	21.62	Methylprednisolone 80 mg inj
J1050	0.95	Medroxyprogesterone acetate
J1071	0.05	Inj testosterone cypionate
J1100	0.19	Dexamethasone sodium phos
J1580	2.85	Garamycin gentamicin inj
J1750	22.89	Inj iron dextran
J1885	0.87	Ketorolac tromethamine inj
J2250	0.22	Inj midazolam hydrochloride
J2550	3.46	Promethazine hcl injection

J2930	11.65	Methylprednisolone injection
J3301	2.86	Triamcinolone acet inj nos
J3420	2.93	Vitamin b12 injection
J7325	19.94	Synvisc or synvisc-one
J7613	0.08	Albuterol non-comp unit
J8540	0.11	Oral dexamethasone
Q0091	83.56	Obtaining screen pap smear
Q2035	30.65	Afluria vacc, 3 yrs & >, im
11100	166.64	Skin biopsy
36415	3.83	Routine venipuncture
90649	290.65	4vhpv vaccine 3 dose im
90651	394.08	9vhpv vaccine 2/3 dose im
90707	135.6	Mmr vaccine sc
90713	60.66	Poliovirus ipv sc/im
90716	234.6	Var vaccine live subq
90734	221.9	Menacwyd/menacwycrm vacc im
90736	386.23	Hzv vaccine live subq
97001	121.06	Physical therapy evaluation
97002	64.42	Physical therapy evaluation
97010	9.06	Hot or cold packs therapy
97033	41.34	Electric current therapy
G0008	20.51	Admin influenza virus vac
Q2038	22.58	Fluzone vacc, 3 yrs & >, im

eTable 3. Unadjusted descriptive statistics among persons primarily using the on-site clinic versus primarily using the near-site clinics for their primary care evaluation and management visits.

Demographics	Primarily using near-site clinics	Primarily using on-site clinic	P value	Standardized mean difference
N	1058	925	-	-
Age, yrs (SD)	31.3 (8.7)	30.3 (8.3)	0.010	0.116
Female, N (%)	204 (19.3)	107 (11.6)	<0.001	0.215
HCC risk score (including those at zero risk, SD)	0.002 (0.023)	0.002 (0.023)	0.947	0.003
Months of enrollment (SD)	34.9 (13.1)	32.8 (14.2)	0.001	0.155
Spending (\$US 2019)				
Total medical and pharmaceutical, mean (SD)	278.7 (674.5)	119.7 (223.4)	<0.001	0.316
Pharmaceutical, mean (SD)	41.5 (226.0)	12.1 (46.4)	<0.001	0.180
Emergency room, mean (SD)	39.6 (173.3)	2.3 (15.9)	<0.001	0.303
Hospitalization, mean (SD)	7.2 (79.2)	1.1 (29.6)	0.028	0.102
Primary care, mean (SD)	22.7 (25.3)	22.6 (45.2)	0.968	0.002
Specialist, mean (SD)	3.2 (6.2)	1.7 (6.0)	<0.001	0.246
Mental health, mean (SD)	7.0 (44.3)	6.7 (24.8)	0.87	0.008
Physical therapy, mean (SD)	6.3 (22.3)	13.8 (52.4)	<0.001	0.186
Drug administration, mean (SD)	8.7 (114.6)	5.7 (19.7)	0.428	0.037
Surgery, mean (SD)	23.3 (122.0)	3.3 (19.7)	<0.001	0.229
Labs/pathology, mean (SD)	9.2 (19.5)	2.1 (4.6)	<0.001	0.505
Imaging, mean (SD)	7.4 (33.5)	2.4 (30.3)	0.001	0.155
Utilization (per 1,000 member-months)				
Emergency room, mean (SD)	90.3 (296.7)	6.4 (48.2)	<0.001	0.395
Hospitalization, mean (SD)	5.8 (45.0)	0.1 (2.4)	<0.001	0.179
Primary care, mean (SD)	144.4 (149.1)	137.7 (270.8)	0.489	0.031
Specialist, mean (SD)	25.9 (43.6)	12.4 (43.4)	<0.001	0.310
Mental health, mean (SD)	36.7 (212.9)	40.4 (150.9)	0.662	0.020
Physical therapy, mean (SD)	135.3 (500.8)	196.2 (729.9)	0.029	0.097
Drug administration, mean (SD)	73.3 (168.5)	79.7 (275.4)	0.527	0.028
Surgery, mean (SD)	40.0 (122.6)	12.1 (47.4)	<0.001	0.300
Labs/pathology, mean (SD)	391.3 (511.0)	127.5 (329.6)	<0.001	0.614
Imaging, mean (SD)	43.8 (98.3)	12.4 (50.2)	<0.001	0.402
Cost per utilization episode (\$US 2019)				
Emergency room, mean (SD)	331.6 (207.0)	784.6 (666.3)	<0.001	0.918
Hospitalization, mean (SD)	1611.2 (2236.5)	6468.7 (5966.7)	<0.001	1.078
Primary care, mean (SD)	155.5 (38.5)	166.3 (42.3)	<0.001	0.269
Specialist, mean (SD)	124.1 (50.2)	145.3 (48.6)	<0.001	0.430
Mental health, mean (SD)	134.3 (246.5)	144.7 (144.0)	0.259	0.052
Physical therapy, mean (SD)	61.9 (42.9)	67.5 (35.9)	0.002	0.142
Drug administration, mean (SD)	81.6 (150.1)	68.9 (119.6)	0.039	0.094
Surgery, mean (SD)	347.8 (1167.7)	217.1 (308.2)	0.001	0.153
Labs/pathology, mean (SD)	28.2 (34.4)	22.3 (20.0)	<0.001	0.210
Imaging, mean (SD)	127.9 (218.7)	122.5 (156.0)	0.529	0.029

eTable 4. Percent differences in spending (\$US 2019).

Percent differences in spending per member per month among those typically utilizing the on-site/near-site clinics for primary care, relative to those using off-site clinics, estimated through multivariable adjusted regressions after matching. Not displayed are the 3,022 rows of additional Clinical Classifications Software (CCS) dummy variables, and home zip codes across all members, which were additional controls in all regressions. 95% confidence intervals in parentheses. * p<0.05; ** p<0.01; *** p<0.001

	Total Spend	Emergency	Hospital	Primary Care	Specialist	Mental Health	Physical Therapy	Rx	Drug administration	Surgery	Labs	Radiology
Treatment group, versus control	-45.0***	-32.8***	-15.5***	108.7**	-53.8***	19.8***	9	-25.5***	-4.7	-42.8***	-31.9***	-41.3***
	(-55.1, -34.9)	(-43.9, -21.7)	(-21.5, -9.5)	(101.6, 115.9)	(-61.1, -46.4)	(12.8, 26.9)	(-0.2, 18.2)	(-35.4, -15.5)	(-12.5, 3.1)	(-53.0, -32.6)	(-40.0, -23.9)	(-49.4, -33.2)
Age, yrs	0.8***	-0.4	-0.4**	0.4**	1.2***	-0.1	1.1***	2.1***	-1.9***	1.7***	1.7***	1.7***
	(0.4, 1.3)	(-0.9, 0.1)	(-0.6, -0.1)	(0.1, 0.8)	(0.8, 1.5)	(-0.4, 0.2)	(0.7, 1.5)	(1.6, 2.5)	(-2.3, -1.5)	(1.2, 2.1)	(1.4, 2.1)	(1.4, 2.1)
Female	38.3***	0.6	3.7	23.7***	-2.3	9.4	-11.1	138.7**	4.3	33.6***	53.3***	46.8***
	(23.7, 52.9)	(-15.5, 16.7)	(-5.0, 12.3)	(13.4, 33.9)	(-12.9, 8.2)	(-0.8, 19.5)	(-24.4, 2.2)	(124.3, 153.2)	(-7.0, 15.6)	(18.8, 48.3)	(41.7, 64.9)	(35.1, 58.4)
Months of enrollment	-3.1***	-0.4	-0.3*	-2.5***	-0.6***	-0.4*	-0.2	-1.6***	-0.8***	0.03	-1.4***	-0.3
	(-3.5, -2.7)	(-0.9, 0.04)	(-0.5, -0.01)	(-2.8, -2.2)	(-0.9, -0.2)	(-0.7, -0.1)	(-0.6, 0.2)	(-2.1, -1.2)	(-1.1, -0.5)	(-0.4, 0.5)	(-1.8, -1.1)	(-0.7, 0.01)
HCC risk score	-8.2	-68.6	54.3	-31.5	-27.6	-55.1	-78.1	598.5**	1,121.1***	-48.6	-40	-79.8
	(-366.8, 350.5)	(-486.3, 349.2)	(-115.5, 224.2)	(-246.1, 183.2)	(-250.4, 195.2)	(-266.2, 156.0)	(-389.1, 232.9)	(246.6, 950.4)	(876.5, 1,365.7)	(-412.3, 315.1)	(-295.1, 215.2)	(-336.5, 176.8)
Observations	3,966	3,966	3,966	3,966	3,966	3,966	3,966	3,966	3,966	3,966	3,966	3,966
Log Likelihood	-7,270.50	-7,639.10	-5,244.50	-5,918.00	-6,022.30	-5,871.00	-6,912.40	-7,223.80	-6,278.50	-7,304.70	-6,393.00	-6,408.50
Akaike Inf. Crit.	14,998.90	15,736.10	10,947.00	12,293.90	12,502.60	12,200.00	14,282.80	14,905.60	13,015.00	15,067.50	13,244.00	13,274.90

eTable 5. Percent differences in utilization (encounters per 1,000 member months).

Percent differences in utilization by place of service and type of provider among those typically utilizing the on-site/near-site clinics for primary care, relative to those using off-site clinics, estimated through multivariable adjusted regressions after matching. Not displayed are the 3,022 rows of additional Clinical Classifications Software (CCS) dummy variables, and home zip codes across all members, which were additional controls in all regressions. 95% confidence intervals in parentheses. * p<0.05; ** p<0.01; *** p<0.001

	Emergency	Hospital	Primary Care	Specialist	Mental Health	Physical Therapy	Drug admin	Surgery	Labs	Radiology
Treatment group, versus control	-2.5***	-0.9***	1.2**	-4.9***	1.1**	-2.9**	-2.5***	-4.0***	-6.4***	-3.4***
	(-3.5, -1.5)	(-1.2, -0.5)	(0.4, 2.0)	(-5.5, -4.4)	(0.4, 1.8)	(-4.8, -1.1)	(-3.5, -1.6)	(-4.7, -3.2)	(-8.2, -4.6)	(-3.9, -2.8)
Age, yrs	-0.01	-0.03**	0.03	0.1***	0.01	0.2***	-0.2***	0.1***	0.4***	0.1***
	(-0.1, 0.03)	(-0.04, -0.01)	(-0.01, 0.1)	(0.1, 0.1)	(-0.02, 0.04)	(0.1, 0.3)	(-0.3, -0.2)	(0.1, 0.1)	(0.3, 0.5)	(0.1, 0.1)
Female	0.3	-0.01	1.9**	-0.4	1.5**	-1.4	-1	2.6***	12.1***	3.2***
	(-1.1, 1.7)	(-0.5, 0.5)	(0.7, 3.0)	(-1.2, 0.5)	(0.6, 2.5)	(-4.1, 1.2)	(-2.4, 0.3)	(1.5, 3.6)	(9.6, 14.7)	(2.4, 4.0)
Months of enrollment	-0.2***	-0.03***	-0.4***	-0.1***	-0.1***	-0.2***	-0.2***	-0.1***	-0.7***	-0.1***
	(-0.2, -0.1)	(-0.04, -0.01)	(-0.4, -0.4)	(-0.2, -0.1)	(-0.1, -0.04)	(-0.3, -0.1)	(-0.3, -0.2)	(-0.1, -0.1)	(-0.7, -0.6)	(-0.1, -0.1)
HCC risk score	-7.3	3.2	17.3*	13.3*	-3.9	-26	25.4*	8.7	30	-9.6
	(-29.0, 14.4)	(-3.9, 10.3)	(0.1, 34.6)	(1.2, 25.5)	(-18.3, 10.6)	(-68.6, 16.5)	(4.6, 46.2)	(-7.3, 24.6)	(-10.2, 70.3)	(-21.9, 2.7)
Observations	3,656	3,656	3,656	3,656	3,656	3,656	3,656	3,656	3,656	3,656
Log Likelihood	1,826.10	5,708.90	1,640.00	3,525.30	3,421.60	-166.5	1,452.10	2,820.90	-712.6	3,392.10
Akaike Inf. Crit.	-3,168.20	-10,933.90	-2,796.00	-6,566.60	-6,359.20	817	-2,420.20	-5,157.90	1,909.20	-6,300.10

eTable 6. Percent differences in spending per encounter (\$US 2019/encounter).

Percent differences in spending per encounter by place of service and type of provider among those typically utilizing the on-site/near-site clinics for primary care, relative to those using off-site clinics, estimated through multivariable adjusted regressions after matching. Not displayed are the 3,022 rows of additional Clinical Classifications Software (CCS) dummy variables, and home zip codes across all members, which were additional controls in all regressions. 95% confidence intervals in parentheses. * p<0.05; ** p<0.01; *** p<0.001

	Emergency	Hospital	Primary Care	Specialist	Mental Health	Physical Therapy	Drug admin	Surgery	Labs	Radiology
Treatment group, versus control	23.5***	245.6***	32.5***	17.9***	-17.4***	59.5***	13.4***	-5.8	5.0*	-9.3*
	(17.8, 29.2)	(232.2, 259.0)	(29.9, 35.0)	(14.2, 21.7)	(-27.5, -7.3)	(54.9, 64.1)	(6.2, 20.6)	(-17.5, 5.9)	(0.1, 9.9)	(-16.9, -1.7)
Age, yrs	-0.3**	-0.2	0.3***	-0.02	0.2	0.5***	-0.9***	1.0***	1.2***	1.9***
	(-0.6, -0.1)	(-0.8, 0.4)	(0.2, 0.4)	(-0.2, 0.2)	(-0.2, 0.7)	(0.3, 0.7)	(-1.2, -0.6)	(0.5, 1.5)	(1.0, 1.4)	(1.6, 2.3)
Female	-21.8***	-31.6**	-3.7*	-4	-0.04	-12.5***	32.0***	-5.1	12.3***	1.6
	(-30.0, -13.6)	(-51.0, -12.1)	(-7.4, -0.04)	(-9.4, 1.4)	(-14.6, 14.6)	(-19.2, -5.9)	(21.7, 42.4)	(-22.0, 11.9)	(5.3, 19.4)	(-9.4, 12.6)
Months of enrollment	0.2	0.6*	-0.1	0.1	0.4	-0.3*	-0.2	-0.7**	-0.01	0.3*
	(-0.03, 0.5)	(0.1, 1.2)	(-0.2, 0.003)	(-0.04, 0.3)	(-0.1, 0.8)	(-0.5, -0.1)	(-0.5, 0.1)	(-1.1, -0.2)	(-0.2, 0.2)	(0.02, 0.7)
HCC risk score	-83.2	4,388.9***	-35.6	-66.6	-99.9	-86.6	1,617.3**	33.4	-64.5	-57.8
	(-242.9, 76.5)	(3,813.9, 4,963.9)	(-95.9, 24.8)	(-161.1, 28.0)	(-458.5, 258.6)	(-208.7, 35.6)	(1,400.4, 1,834.2)	(-420.5, 487.2)	(-195.3, 66.4)	(-293.0, 177.4)
Observations	3,966	3,966	3,966	3,966	3,966	3,966	3,966	3,966	3,966	3,966
Log Likelihood	-5,062.00	-8,361.40	-1,899.10	-3,418.00	-7,269.70	-4,239.80	-5,946.70	-7,832.80	-4,454.50	-6,171.70
Akaike Inf. Crit.	10,581.90	17,180.90	4,256.30	7,294.00	14,997.40	8,937.50	12,351.50	16,123.60	9,367.00	12,801.40

eTable 7. Sensitivity analysis on percent differences in spending (\$US 2019).

Percent differences in spending, per member per month among those typically utilizing the on-site/near-site clinics for primary care, relative to those using off-site clinics, after excluding newborns, those with neonatal intensive care unit admissions, pregnancy, dialysis, hospice, rehabilitation, or organ transplant histories; those members with over \$50,000 in claims spending per year; those with less than 11 months of enrollment; or those with only medical examination or immunization as modal principal diagnoses, estimated through multivariable adjusted regressions after matching. Not displayed are the 3,022 rows of additional Clinical Classifications Software (CCS) dummy variables, and home zip codes across all members, which were additional controls in all regressions. 95% confidence intervals in parentheses. * p<0.05;

** p<0.01; *** p<0.001

	Total Spend	Emergency	Hospital	Primary Care	Specialist	Mental Health	Physical Therapy	Rx	Drug administration	Surgery	Labs	Radiology
Treatment group, versus control	-48.5***	-38.1***	-16.4**	100.7**	-55.5***	16.6***	-0.2	-31.0***	-1	-42.4***	-29.4***	-44.7***
	(-60.1, -36.8)	(-50.8, -25.5)	(-23.5, -9.4)	(92.7, 108.8)	(-63.6, -47.4)	(8.4, 24.7)	(-10.6, 10.3)	(-42.3, -19.7)	(-9.7, 7.7)	(-54.3, -30.6)	(-38.5, -20.3)	(-54.0, -35.3)
Age, yrs	0.7*	-0.7*	-0.2	0.6**	1.1***	-0.3	1.1***	1.9***	-1.8***	1.7***	1.6***	1.6***
	(0.2, 1.2)	(-1.2, -0.1)	(-0.5, 0.2)	(0.2, 0.9)	(0.7, 1.5)	(-0.6, 0.1)	(0.7, 1.6)	(1.4, 2.4)	(-2.2, -1.4)	(1.2, 2.3)	(1.2, 2.0)	(1.2, 2.0)
Female	56.6***	6	7.1	28.1***	2.9	3.3	-7.6	160.3**	10.1	37.8***	73.0***	55.6***
	(40.0, 73.2)	(-12.1, 24.0)	(-2.9, 17.2)	(16.6, 39.5)	(-8.6, 14.5)	(-8.3, 14.9)	(-22.5, 7.4)	(144.2, 176.4)	(-2.2, 22.5)	(20.9, 54.8)	(60.0, 86.0)	(42.3, 68.8)
Months of enrollment	-3.0***	-0.8**	-0.2	-2.1***	-0.7***	-0.5*	-0.5*	-1.7***	-1.0***	-0.2	-1.5***	-0.7**
	(-3.5, -2.4)	(-1.4, -0.2)	(-0.5, 0.1)	(-2.5, -1.7)	(-1.1, -0.3)	(-0.9, -0.1)	(-1.0, -0.001)	(-2.3, -1.2)	(-1.4, -0.6)	(-0.8, 0.3)	(-1.9, -1.0)	(-1.1, -0.2)
HCC risk score	-22.9	-79.3	-46.1	-45.2	-63.6	-43.3	-52.2	936.7**	1,957.1***	-51	-66.9	-79
	(-484.7, 438.9)	(-614.1, 455.5)	(-263.9, 171.7)	(-306.5, 216.0)	(-328.1, 200.8)	(-308.3, 221.6)	(-442.3, 338.0)	(496.5, 1,376.9)	(1,665.7, 2,248.5)	(-530.0, 428.0)	(-381.3, 247.6)	(-404.6, 246.6)
Observations	3,014	3,014	3,014	3,014	3,014	3,014	3,014	3,014	3,014	3,014	3,014	3,014
Log Likelihood	-5,469.30	-5,720.40	-4,014.80	-4,392.70	-4,417.30	-4,421.60	-5,167.70	-5,385.10	-4,611.80	-5,533.00	-4,760.70	-4,828.20

Akaike Inf. Crit.	11,364 .60	11,866 .80	8,455. 60	9,211. 40	9,260. 60	9,269.1 0	10,761.4 0	11,196 .20	9,649 .50	11,491 .90	9,947. 40	10,082 .50
----------------------	---------------	---------------	--------------	--------------	--------------	--------------	---------------	---------------	--------------	---------------	--------------	---------------

eTable 8. Sensitivity analysis on percent differences in utilization (encounters per 1,000 member months).

Percent differences in utilization by place of service and type of provider among those typically utilizing the on-site/near-site clinics for primary care, relative to those using off-site clinics, after excluding newborns, those with neonatal intensive care unit admissions, pregnancy, dialysis, hospice, rehabilitation, or organ transplant histories; those members with over \$50,000 in claims spending per year; those with less than 11 months of enrollment; or those with only medical examination or immunization as modal principal diagnoses, estimated through multivariable adjusted regressions after matching. Not displayed are the 3,022 rows of additional Clinical Classifications Software (CCS) dummy variables, and home zip codes across all members, which were additional controls in all regressions. 95% confidence intervals in parentheses. * p<0.05;

** p<0.01; *** p<0.001

	Emergency	Hospital	Primary Care	Specialist	Mental Health	Physical Therapy	Drug admin	Surger y	Labs	Radiology
Treatment group, versus control	-3.0***	-0.8***	0.7	-4.8***	0.8*	-4.7***	-1.9***	-3.7***	-5.5***	-3.7***
	(-4.1, -2.0)	(-1.2, -0.4)	(-0.02, 1.5)	(-5.3, -4.2)	(0.2, 1.5)	(-6.7, -2.7)	(-2.8, -1.0)	(-4.5, -2.9)	(-7.3, -3.7)	(-4.4, -3.0)
Age, yrs	-0.04	-0.003	0.04*	0.1***	0.01	0.2***	-0.2***	0.1***	0.3***	0.1***
	(-0.1, 0.01)	(-0.02, 0.01)	(0.01, 0.1)	(0.04, 0.1)	(-0.03, 0.04)	(0.1, 0.3)	(-0.2, -0.1)	(0.1, 0.1)	(0.3, 0.4)	(0.1, 0.1)
Female	1	0.2	3.1***	-0.01	0.3	-0.9	-0.3	3.0***	15.1***	3.8***
	(-0.5, 2.5)	(-0.3, 0.7)	(2.0, 4.1)	(-0.8, 0.7)	(-0.6, 1.3)	(-3.8, 2.0)	(-1.6, 1.0)	(1.8, 4.1)	(12.6, 17.7)	(2.9, 4.7)
Months of enrollment	-0.1***	-0.01	-0.2***	-0.1***	-0.1***	-0.2***	-0.2***	-0.1***	-0.5***	-0.1***
	(-0.2, -0.1)	(-0.03, 0.01)	(-0.3, -0.2)	(-0.1, -0.1)	(-0.1, -0.02)	(-0.3, -0.1)	(-0.2, -0.1)	(-0.1, -0.04)	(-0.6, -0.4)	(-0.1, -0.1)
HCC risk score	-9.7	-2.8	5.3	-0.2	-2	-14.5	28.8**	7.5	-10.4	-8.2
	(-33.0, 13.6)	(-10.8, 5.1)	(-11.1, 21.8)	(-11.7, 11.3)	(-16.6, 12.7)	(-62.1, 33.0)	(8.9, 48.7)	(-10.7, 25.7)	(-51.9, 31.1)	(-22.4, 6.0)
Observations	3,014	3,014	3,014	3,014	3,014	3,014	3,014	3,014	3,014	3,014
Log Likelihood	1,694.30	4,832.50	2,698.20	3,748.90	3,038.70	-288.4	2,145.40	2,400.30	80.5	3,126.50
Akaike Inf. Crit.	-2,962.60	-9,239.00	-4,970.30	-7,071.80	-5,651.40	1,002.90	-3,864.80	-4,374.60	265.1	-5,827.00

eTable 9. Sensitivity analysis on percent differences in spending per encounter (\$US 2019/encounter).

Spending per encounter by place of service and type of provider among those typically utilizing the on-site/near-site clinics for primary care, relative to those using off-site clinics, after excluding newborns, those with neonatal intensive care unit admissions, pregnancy, dialysis, hospice, rehabilitation, or organ transplant histories; those members with over \$50,000 in claims spending per year; those with less than 11 months of enrollment; or those with only medical examination or immunization as modal principal diagnoses, estimated through multivariable adjusted regressions after matching. Not displayed are the 3,022 rows of additional Clinical Classifications Software (CCS) dummy variables, and home zip codes across all members, which were additional controls in all regressions. 95% confidence intervals in parentheses. * p<0.05; ** p<0.01; *** p<0.001

	Emergency	Hospital	Primary Care	Specialist	Mental Health	Physical Therapy	Drug admin	Surgery	Labs	Radiology
Treatment group, versus control	20.5***	249.9***	29.8***	16.5***	-16.6**	62.3***	13.3**	-5.3	5.8*	-10.1*
	(14.0, 27.0)	(234.3, 265.6)	(27.1, 32.6)	(12.2, 20.8)	(-28.0, -5.2)	(56.8, 67.7)	(5.1, 21.5)	(-19.1, 8.4)	(0.1, 11.4)	(-18.8, -1.5)
Age, yrs	-0.2	-0.2	0.3***	0.01	0.4	0.6***	-1.0***	1.2***	1.2***	1.9***
	(-0.5, 0.1)	(-0.9, 0.5)	(0.2, 0.4)	(-0.2, 0.2)	(-0.1, 1.0)	(0.3, 0.8)	(-1.4, -0.7)	(0.6, 1.9)	(0.9, 1.4)	(1.5, 2.3)
Female	-25.9***	-34.6**	-5.9**	-6.8*	-4.3	-10.9**	39.7***	-5.3	15.0***	7.1
	(-35.2, -16.6)	(-57.0, -12.2)	(-9.8, -2.0)	(-12.9, -0.6)	(-20.6, 12.0)	(-18.6, -3.3)	(28.1, 51.3)	(-24.9, 14.4)	(6.9, 23.0)	(-5.3, 19.5)
Months of enrollment	0.1	0.4	-0.1*	0.03	0.1	-0.3*	-0.1	-1.1***	-0.03	0.4
	(-0.2, 0.4)	(-0.3, 1.2)	(-0.3, -0.002)	(-0.2, 0.2)	(-0.5, 0.6)	(-0.6, -0.1)	(-0.4, 0.3)	(-1.8, -0.5)	(-0.3, 0.2)	(-0.03, 0.8)
HCC risk score	7.6	6,489.3***	-33.7	-76.8	-99.8	-86.4	1,452.1**	-42.2	-60.8	-24.9
	(-186.9, 202.2)	(5,699.1, 7,279.5)	(-100.5, 33.2)	(-190.8, 37.2)	(-549.7, 350.0)	(-238.1, 65.3)	(1,185.0, 1,719.2)	(-660.9, 576.4)	(-222.5, 101.0)	(-316.6, 266.7)
Observations	3,014	3,014	3,014	3,014	3,014	3,014	3,014	3,014	3,014	3,014
Log Likelihood	-3,772.10	-6,338.90	-1,197.40	-2,541.50	-5,423.40	-3,214.90	-4,437.60	-5,959.40	-3,361.50	-4,613.50

Akaike Inf. Crit.	7,970.1 0	13,103.8 0	2,820.80	5,509.0 0	11,272.90	6,855.80	9,301.1 0	12,344.8 0	7,149.0 0	9,653.0 0
-------------------	--------------	---------------	----------	--------------	-----------	----------	--------------	---------------	--------------	--------------

eTable 10. Descriptive statistics for the primary treatment group versus the alternative control group of unsubsidized members from other employers.

The treatment group are those using the subsidized on-site/near-site primary care clinics for the majority of primary care evaluation and management visits, while the control group are those in similar preferred-provider-organization health plans sponsored by employers who did not have available an on-site/near-site primary care clinic, and did not get subsidized use of on-site/near-site primary care clinics. The matching included all 3,022 Clinical Classifications Software (CCS) categories, of which the top five most prevalent are listed here. SD: standard deviation.

Characteristic	Group		Standardized Mean Difference
	Control	Treatment	
Before matching			
N	31,497	1,973	-
Age, yrs (SD)	27.7 (15.6)	30.5 (8.5)	0.223
Female, %	13294 (42.2)	313 (14.7)	0.641
HCC risk score (including those at zero risk, SD)	0.086 (0.329)	0.073 (0.181)	0.048
HCC risk score (for those above zero risk, SD)	0.586 (0.668)	0.424 (0.204)	0.332
Months of enrollment (SD)	25.6 (15.5)	32.6 (14.2)	0.467
Common CCS diagnosis categories			
Medical examination/evaluation, N (%)	1467 (4.7)	431 (21.8)	5.523
Immunizations and screening for infectious disease, N (%)	244 (0.8)	641 (32.5)	6.584
Spondylosis; intervertebral disc disorders; other back problems, N (%)	525 (1.7)	98 (5.0)	13.218
Other upper respiratory infections, N (%)	211 (0.7)	44 (2.2)	30.022
Other non-traumatic joint disorders, N (%)	207 (0.7)	77 (3.9)	22.396
Highest-cost CCS diagnostic categories (\$US 2019)			
Secondary malignancies, \$67,482 PMPM	1 (<0.1)	0 (0.0)	31499.000
Non-Hodgkin's lymphoma, \$25,398 PMPM	1 (<0.1)	0 (0.0)	31499.000
Multiple myeloma, \$22,410 PMPM	2 (<0.1)	0 (0.0)	15750.500
Hodkin's disease, \$22,017 PMPM	1 (<0.1)	0 (0.0)	31499.000
Ectopic pregnancy, \$20,936 PMPM	4 (<0.1)	0 (0.0)	7876.250
After matching			
N	1,680	1,680	-
Age, yrs (SD)	30.2 (14.6)	30.5 (8.7)	0.028
Female, %	301 (17.9)	304 (18.1)	0.005

HCC risk score (including those at zero risk, SD)	0.082 (0.237)	0.079 (0.187)	0.014
HCC risk score (for those above zero risk, SD)	0.488 (0.369)	0.422 (0.206)	0.370
Months of enrollment (SD)	31.3 (14.8)	31.4 (14.4)	0.010
Common CCS diagnostic categories			
Medical examination/evaluation, N (%)	389 (23.2)	395 (23.5)	0.056
Immunizations and screening for infectious disease, N (%)	457 (27.2)	483 (28.8)	0.191
Spondylosis; intervertebral disc disorders; other back problems, N (%)	98 (5.8)	90 (5.4)	0.852
Other upper respiratory infections, N (%)	46 (2.7)	42 (2.5)	1.827
Other non-traumatic joint disorders, N (%)	72 (4.3)	68 (4.0)	0.746
Highest-cost diagnostic categories (\$US 2019)			
Cardiac and circulatory congenital anomalies, N (%) \$8847 PMPM	1 (<0.1)	2 (0.1)	336.721
Heart valve disorders, N (%) \$5004 PMPM	3 (0.2)	2 (0.1)	129.646
Other acquired deformities, N (%) \$4553 PMPM	4 (0.2)	4 (0.2)	0.000
Chronic kidney disease, N (%) \$4262 PMPM	2 (0.1)	1 (<0.1)	336.721
Genitourinary symptoms and ill-defined conditions, N (%) \$2104 PMPM	24 (1.4)	25 (1.5)	1.441

eTable 11. Sensitivity analysis of alternative control group.

Unadjusted outcome rates among the study population, before and after the treated population was matched to the alternative control group of unsubsidized members from other employers.

	Spend		Utilization		Spend per encounter	
	(US\$ 2019/member/month)		(encounters/1,000 member months)		(\$US 2019/encounter)	
Before match	Control	Treatment	Control	Treatment	Control	Treatment
	(N = 31,497)	(N = 2,133)	(N = 31,497)	(N = 2,133)	(N = 31,497)	(N = 2,133)
Total medical and pharmaceutical, mean (SD)	251.3 (1764.4)	219.5 (536.8)				
Pharmaceutical, mean (SD)	61.8 (678.5)	38.4 (236.6)				
Emergency room, mean (SD)	10.2 (104.9)	18.8 (100.6)	29.8 (371.5)	52.5 (224.6)	399.9 (282.6)	391.4 (340.0)
Hospitalization, mean (SD)	8.7 (388.4)	5.5 (89.5)	3.6 (72.6)	2.5 (30.0)	2523.1 (4728.4)	2791.0 (6504.5)
Primary care, mean (SD)	8.9 (42.1)	25.6 (41.3)	61.6 (337.0)	159.7 (246.8)	162.1 (83.7)	161.7 (42.2)
Specialist, mean (SD)	4.2 (32.6)	2.9 (6.7)	34.9 (263.2)	22.9 (48.2)	133.1 (77.3)	125.7 (53.6)
Mental health, mean (SD)	2.6 (44.0)	7.5 (44.4)	13.8 (210.9)	44.8 (255.0)	218.8 (416.6)	195.4 (322.0)
Physical therapy, mean (SD)	4.0 (44.2)	11.8 (57.9)	96.1 (993.3)	196.8 (880.4)	49.2 (59.2)	68.0 (39.8)
Drug administration, mean (SD)	3.8 (81.7)	7.6 (81.9)	29.8 (219.0)	81.0 (221.2)	93.1 (272.0)	73.7 (107.0)
Surgery, mean (SD)	26.9 (374.4)	14.1 (92.4)	33.3 (306.3)	26.9 (91.8)	543.5 (1815.6)	363.8 (1595.1)
Labs/pathology, mean (SD)	6.3 (58.1)	6.5 (15.5)	155.8 (1062.0)	313.7 (529.2)	42.2 (98.5)	25.5 (28.7)
Imaging, mean (SD)	8.6 (184.2)	4.9 (29.4)	28.1 (228.5)	33.2 (98.7)	227.6 (317.9)	129.2 (190.7)
After match	Control	Treatment	Control	Treatment	Control	Treatment
	(N = 1,680)	(N = 1,680)	(N = 1,680)	(N = 1,680)	(N = 1,680)	(N = 1,680)
Total medical and pharmaceutical, mean (SD)	658.7 (2383.3)	224.0 (553.9)				
Pharmaceutical, mean (SD)	72.9 (385.2)	37.0 (240.1)				

Emergency room, mean (SD)	37.0 (154.6)	22.2 (112.2)	116.1 (766.7)	61.1 (248.5)	288.0 (124.0)	280.7 (118.9)
Hospitalization, mean (SD)	34.1 (383.4)	4.0 (61.4)	10.8 (84.8)	2.8 (33.4)	1050.7 (4348.2)	1064.2 (4451.9)
Primary care, mean (SD)	29.8 (63.3)	25.6 (34.6)	197.0 (466.7)	159.5 (204.0)	144.0 (89.2)	162.0 (43.6)
Specialist, mean (SD)	13.5 (49.7)	3.1 (7.1)	107.0 (404.3)	24.2 (50.3)	84.5 (89.0)	43.5 (68.0)
Mental health, mean (SD)	9.8 (80.9)	7.5 (39.6)	52.4 (368.9)	43.4 (207.2)	29.4 (125.8)	31.1 (158.3)
Physical therapy, mean (SD)	9.0 (36.0)	11.5 (57.8)	224.0 (837.8)	198.8 (901.3)	17.1 (41.3)	27.9 (43.7)
Drug administration, mean (SD)	11.0 (69.1)	7.4 (91.3)	115.1 (354.0)	72.3 (162.0)	38.8 (149.8)	39.1 (88.2)
Surgery, mean (SD)	77.8 (554.7)	14.7 (94.4)	79.9 (305.1)	28.2 (96.4)	252.1 (1971.2)	106.7 (904.0)
Labs/pathology, mean (SD)	14.1 (65.8)	6.7 (16.3)	419.5 (1262.1)	328.9 (532.2)	27.2 (47.4)	24.0 (26.4)
Imaging, mean (SD)	17.2 (76.4)	5.6 (32.8)	69.5 (176.9)	35.5 (99.3)	97.2 (218.5)	46.2 (122.6)

eTable 12. Sensitivity analysis on percent differences in spending (\$US 2019).

Percent differences in spending per member per month among those typically utilizing the on-site/near-site clinics for primary care, relative to the alternative control group of members from other employers without access to the on-site/near-site clinical offering, estimated through multivariable adjusted regressions after matching. Not displayed are the 3,022 rows of additional Clinical Classifications Software (CCS) dummy variables, and home zip codes across all members, which were additional controls in all regressions. 95% confidence intervals in parentheses. * p<0.05; ** p<0.01; *** p<0.001

	Total Spend	Emergency	Hospital	Primary Care	Specialist	Mental Health	Physical Therapy	Rx	Drug admin	Surgery	Labs	Radiology
Treatment group, versus control	-54.9***	-19.3**	-14.7**	21.9***	-56.7***	-6.4	32.2***	-43.4***	-5.6	-42.6***	-29.8***	-46.3***
	(-67.1, -42.8)	(-33.1, -5.4)	(-22.2, -7.2)	(13.2, 30.5)	(-67.0, -46.3)	(-15.1, 2.3)	(22.5, 41.8)	(-58.1, -28.8)	(-15.8, 4.6)	(-55.7, -29.5)	(-40.2, -19.5)	(-57.7, -35.0)
Age, yrs	0.4	-0.2	-0.5***	-0.6***	0.4*	0.1	0.1	1.3***	-1.6***	1.1***	1.1***	0.6**
	(-0.03, 0.8)	(-0.7, 0.2)	(-0.7, -0.2)	(-0.9, -0.3)	(0.1, 0.8)	(-0.2, 0.4)	(-0.2, 0.4)	(0.8, 1.8)	(-1.9, -1.3)	(0.6, 1.5)	(0.8, 1.5)	(0.2, 1.0)
Female	-3.9	-6	0.3	-5.6	-16.3**	-6.1	-11.6*	55.1***	10.5	-6.3	12.3*	10
	(-17.5, 9.7)	(-21.5, 9.5)	(-8.1, 8.6)	(-15.2, 4.0)	(-27.8, -4.7)	(-15.8, 3.6)	(-22.4, -0.8)	(38.8, 71.4)	(-0.8, 21.9)	(-20.9, 8.3)	(0.7, 23.8)	(-2.7, 22.7)
Months of enrollment	-3.1***	-0.6**	-0.4***	-3.3***	-0.8***	-0.2	-0.2	-1.1***	-0.7***	-0.5*	-1.5***	-0.4*
	(-3.5, -2.8)	(-1.0, -0.2)	(-0.7, -0.2)	(-3.6, -3.1)	(-1.1, -0.5)	(-0.5, 0.04)	(-0.5, 0.1)	(-1.5, -0.6)	(-1.0, -0.4)	(-0.9, -0.1)	(-1.9, -1.2)	(-0.8, -0.1)
HCC risk score	269.0**	146.6**	81.4**	90.0***	68.1***	69.1***	50.1***	222.8**	10.6	113.3**	90.6***	62.5***
	(243.2, 294.8)	(117.1, 176.1)	(65.7, 97.1)	(71.9, 108.1)	(46.2, 89.9)	(50.8, 87.4)	(29.8, 70.4)	(191.7, 254.0)	(-10.8, 32.1)	(85.5, 141.1)	(68.7, 112.4)	(38.5, 86.5)
Observations	3,360	3,360	3,360	3,360	3,360	3,360	3,360	3,360	3,360	3,360	3,360	3,360
Log Likelihood	-5,680.20	-6,105.40	-4,097.90	-4,546.30	-5,153.70	-4,579.90	-4,918.90	-6,274.30	-5,091.30	-5,912.90	-5,152.40	-5,451.90
Akaike Inf. Crit.	11,920.40	12,770.90	8,755.80	9,652.60	10,867.30	9,719.80	10,397.80	13,108.50	10,742.50	12,385.90	10,864.80	11,463.90

eTable 13. Sensitivity analysis on percent differences in utilization (encounters per 1,000 member months).

Percent differences in utilization by place of service and type of provider among those typically utilizing the on-site/near-site clinics for primary care, relative to the alternative control group of members from other employers without access to the on-site/near-site clinical offering, estimated through multivariable adjusted regressions after matching. Not displayed are the 3,022 rows of additional Clinical Classifications Software (CCS) dummy variables, and home zip codes across all members, which were additional controls in all regressions. 95% confidence intervals in parentheses. * p<0.05; ** p<0.01; *** p<0.001


	Emergency	Hospital	Primary Care	Specialist	Mental Health	Physical Therapy	Drug admin	Surgery	Labs	Radiology
Treatment group, versus control	-2.7***	-0.7***	-3.1***	-5.7***	-1.2**	1	-1.9***	-4.1***	-4.5***	-3.8***
	(-4.1, -1.2)	(-1.1, -0.4)	(-4.3, -1.8)	(-6.7, -4.8)	(-2.1, -0.4)	(-1.2, 3.1)	(-3.0, -0.9)	(-5.1, -3.1)	(-6.9, -2.2)	(-4.6, -2.9)
Age, yrs	0.002	-0.02***	-0.1*	0.1***	0.05**	0.01	-0.2***	0.1**	0.2***	0.02
	(-0.05, 0.1)	(-0.04, -0.01)	(-0.1, -0.01)	(0.02, 0.1)	(0.02, 0.1)	(-0.1, 0.1)	(-0.2, -0.1)	(0.02, 0.1)	(0.1, 0.3)	(-0.003, 0.1)
Female	-1	-0.3	-1.9**	-1.6**	-0.3	-2.8*	-1.4*	-1.3*	3.3*	-0.01
	(-2.6, 0.6)	(-0.8, 0.1)	(-3.3, -0.5)	(-2.7, -0.6)	(-1.3, 0.6)	(-5.2, -0.4)	(-2.6, -0.2)	(-2.4, -0.1)	(0.6, 6.0)	(-0.9, 0.9)
Months of enrollment	-0.2***	-0.04***	-0.6***	-0.2***	-0.1***	-0.2***	-0.2***	-0.2***	-0.8***	-0.1***
	(-0.2, -0.1)	(-0.05, -0.02)	(-0.6, -0.5)	(-0.2, -0.2)	(-0.1, -0.1)	(-0.3, -0.1)	(-0.3, -0.2)	(-0.2, -0.1)	(-0.8, -0.7)	(-0.2, -0.1)
HCC risk score	4.1**	1.9***	6.7***	1	0.1	7.7***	0.9	1.4	15.8***	2.6**
	(1.2, 7.0)	(1.1, 2.6)	(4.1, 9.3)	(-0.9, 2.9)	(-1.7, 1.9)	(3.2, 12.1)	(-1.4, 3.1)	(-0.7, 3.5)	(10.9, 20.8)	(1.0, 4.3)
Observations	3,360	3,360	3,360	3,360	3,360	3,360	3,360	3,360	3,360	3,360
Log Likelihood	1,432.10	5,834.00	1,812.50	2,832.40	3,090.30	44.7	2,330.60	2,605.60	-295.4	3,351.20
Akaike Inf. Crit.	-2,304.20	-11,108.10	-3,065.00	-5,104.80	-5,620.60	470.6	-4,101.10	-4,651.30	1,150.70	-6,142.50

eTable 14. Sensitivity analysis on percent differences in spending per encounter (\$US 2019/encounter).

Spending per encounter by place of service and type of provider among those typically utilizing the on-site/near-site clinics for primary care, relative to the alternative control group of members from other employers without access to the on-site/near-site clinical offering, estimated through multivariable adjusted regressions after matching. Not displayed are the 3,022 rows of additional Clinical Classifications Software (CCS) dummy variables, and home zip codes across all members, which were additional controls in all regressions. 95% confidence intervals in parentheses. * p<0.05; ** p<0.01; *** p<0.001


	Emergency	Hospital	Primary Care	Specialist	Mental Health	Physical Therapy	Drug admin	Surgery	Labs	Radiology
Treatment group, versus control	0.4	8.1	83.4***	-75.1***	-9.7	77.7***	11.7	-53.7***	44.2***	-48.9***
	(-2.4, 3.1)	(-7.3, 23.6)	(73.5, 93.3)	(-94.8, -55.4)	(-23.8, 4.4)	(62.2, 93.3)	(-2.4, 25.8)	(-74.5, -32.9)	(35.9, 52.5)	(-64.9, -33.0)
Age, yrs	-0.1	-0.5	-0.5**	0.7*	0.03	0.03	-1.8***	1.7***	0.6***	0.5
	(-0.2, 0.03)	(-1.0, 0.1)	(-0.9, -0.2)	(0.1, 1.4)	(-0.4, 0.5)	(-0.5, 0.6)	(-2.3, -1.3)	(1.0, 2.4)	(0.4, 0.9)	(-0.01, 1.1)
Female	1.4	10.7	2.2	-23.8*	-9.2	-12.4	21.3**	23.1	14.2**	20.9*
	(-1.7, 4.4)	(-6.5, 28.0)	(-8.8, 13.3)	(-45.8, -1.7)	(-24.9, 6.5)	(-29.7, 5.0)	(5.5, 37.0)	(-0.2, 46.5)	(5.0, 23.5)	(3.1, 38.7)
Months of enrollment	-0.04	0.04	-0.3	1.9***	0.4*	1.2***	1.1***	0.8**	0.1	0.9***
	(-0.1, 0.05)	(-0.4, 0.5)	(-0.6, 0.05)	(1.3, 2.5)	(0.02, 0.9)	(0.7, 1.7)	(0.7, 1.5)	(0.2, 1.4)	(-0.1, 0.4)	(0.4, 1.4)
HCC risk score	7.9**	24.1	20.3	187.8***	155.8***	10.5	7.8	122.1***	19.8*	116.0***
	(2.2, 13.5)	(-8.9, 57.1)	(-0.5, 41.1)	(145.2, 230.5)	(125.9, 185.8)	(-22.7, 43.7)	(-22.2, 37.7)	(76.9, 167.2)	(2.4, 37.2)	(81.9, 150.2)
Observations	3,360	3,360	3,360	3,360	3,360	3,360	3,360	3,360	3,360	3,360
Log Likelihood	-753.4	-6,454.30	-4,999.00	-7,240.70	-6,154.70	-6,473.70	-6,150.20	-7,416.90	-4,423.80	-6,556.80
Akaike Inf. Crit.	2,066.80	13,468.60	10,558.10	15,041.30	12,869.50	13,507.30	12,860.30	15,393.90	9,407.70	13,673.70

eFigure 1. Quantile-quantile plot of log-transformed total medical and pharmaceutical spending (\$US 2019) compared to the theoretically-optimal line for ordinary least squares regression.




eFigure 2. Absolute differences in spending, utilization, and spending per encounter.

(A) Differences in spending. Dollar differences in spending (\$US 2019), per member per month among those most commonly utilizing subsidized on-site/near-site clinics for primary care, relative to those most commonly using unsubsidized off-site clinics. Error bars indicate 95% confidence intervals from multivariable regressions among matched cohorts, adjusted for age, sex, risk score, home zip code, enrollment duration, and modal Clinical Classifications Software (CCS) diagnosis category. Note the total spend refers to the association between on-site/near-site clinic use and total spending (regression coefficient), not the sum of other regression coefficients by subcategory.



(B) Differences in utilization. Absolute differences in utilization (encounters per 1,000 member months) by place of service and type of provider among those most commonly utilizing the subsidized on-site/near-site clinics for primary care, relative to those most commonly utilizing unsubsidized off-site clinics. Error bars indicate 95% confidence intervals from multivariable regressions among matched cohorts, adjusted for age, sex, risk score, home zip code, enrollment duration, and modal Clinical Classifications Software (CCS) diagnosis category. Note the difference in the horizontal axis scale from eFigures 1a and 1c.



(C) Differences in spending per encounter. Dollar differences in spending per encounter (\$US 2019/encounter) by place of service and type of provider among those most commonly utilizing the subsidized on-site/near-site clinics for primary care, relative to those most commonly using unsubsidized off-site clinics. Error bars indicate 95% confidence intervals from multivariable regressions among matched cohorts, adjusted for age, sex, risk score, home zip code, enrollment duration, and modal Clinical Classifications Software (CCS) diagnosis category. Note the difference in horizontal axis scale from eFigures 1a and 1b.

